{"id":544610,"date":"2021-05-25T15:02:01","date_gmt":"2021-05-25T15:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544610"},"modified":"2021-05-25T15:02:01","modified_gmt":"2021-05-25T15:02:01","slug":"primary-sclerosing-cholangitis-psc-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-sclerosing-cholangitis-psc-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544610.html","title":{"rendered":"Primary Sclerosing Cholangitis (PSC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Primary<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cPrimary Sclerosing Cholangitis (PSC) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Primary Sclerosing Cholangitis (PSC) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Primary Sclerosing Cholangitis (PSC) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the  Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per 100,000 in the general population in the United States or Europe.<\/p>\n<\/li>\n

  2. \n

    According to the study<\/p>\n<\/li>\n

      \n
    1. \n

      The prevalence of PSC in ulcerative colitis (UC) has been estimated to be ~5%.<\/p>\n<\/li>\n

    2. \n

      Approximately 60%–70% of patients with PSC and UC are men, and age at diagnosis is usually 30–40 years. Among patients without UC, there is a slight female predominance.<\/p>\n<\/li>\n<\/ol>\n<\/ol>\n

      Key benefits of the report:<\/strong><\/p>\n

      1. Primary Sclerosing Cholangitis (PSC) market report covers a descriptive overview and comprehensive insight of the Primary Sclerosing Cholangitis (PSC) epidemiology and Primary Sclerosing Cholangitis (PSC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

      2. The Primary Sclerosing Cholangitis (PSC) market report provides insights on the current and emerging therapies.<\/p>\n

      3. Primary Sclerosing Cholangitis (PSC) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

      4. The Primary Sclerosing Cholangitis (PSC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Primary Sclerosing Cholangitis (PSC) market.<\/p>\n

      Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/primary-sclerosing-cholangitis-market<\/span><\/a>
      <\/a><\/strong><\/p>\n

      Primary Sclerosing Cholangitis (PSC): Overview<\/strong><\/p>\n

      Primary sclerosing cholangitis (PSC) is a chronic, or long-term, disease that slowly damages the bile ducts. Bile is a digestive liquid that is made in the liver. It travels through the bile ducts to the gallbladder and the small intestine, where it helps digest fats and fatty vitamins.<\/p>\n

      The key players involved in the Primary Sclerosing Cholangitis (PSC) market:<\/strong><\/p>\n

        \n
      1. \n

        Gilead Sciences<\/p>\n<\/li>\n

      2. \n

        HighTide Therapeutics <\/p>\n<\/li>\n

      3. \n

        Tobira Therapeutics<\/p>\n<\/li>\n

      4. \n

        NGM Biopharmaceuticals<\/p>\n<\/li>\n<\/ol>\n

        The launch of the emerging therapies is expected to significantly impact the Primary Sclerosing Cholangitis (PSC) treatment<\/a> scenario in the upcoming years:-<\/strong><\/p>\n

        Drug covered<\/strong><\/p>\n

          \n
        1. \n

          GS-9674<\/p>\n<\/li>\n

        2. \n

          HTD1801 <\/p>\n<\/li>\n

        3. \n

          Cenicriviroc<\/p>\n<\/li>\n

        4. \n

          NGM282 <\/p>\n<\/li>\n<\/ol>\n

          Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/primary-sclerosing-cholangitis-market<\/span><\/a><\/strong><\/p>\n

          Table of Contents<\/strong><\/p>\n

          1. Report Introduction<\/p>\n

          2. Executive Summary<\/p>\n

          3. SWOT analysis<\/p>\n

          4. Primary Sclerosing Cholangitis (PSC) Patient Share (%) Overview at a Glance<\/p>\n

          5. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance<\/p>\n

          6. Primary Sclerosing Cholangitis (PSC) Disease Background and Overview<\/p>\n

          7. Primary Sclerosing Cholangitis (PSC) Epidemiology and Patient Population<\/p>\n

          8. Country-Specific Patient Population of Primary Sclerosing Cholangitis (PSC)<\/p>\n

          9. Primary Sclerosing Cholangitis (PSC) Current Treatment and Medical Practices<\/p>\n

          10. Unmet Needs<\/p>\n

          11. Primary Sclerosing Cholangitis (PSC) Emerging Therapies<\/p>\n

          12. Primary Sclerosing Cholangitis (PSC) Market Outlook<\/p>\n

          13. Country-Wise Primary Sclerosing Cholangitis (PSC) Market Analysis (2017–2030)<\/p>\n

          14. Market Access and Reimbursement of Therapies<\/p>\n

          15. Market drivers<\/p>\n

          16. Market barriers<\/p>\n

          17. Appendix<\/p>\n

          18. Primary Sclerosing Cholangitis (PSC) Report Methodology<\/p>\n

          19. DelveInsight Capabilities<\/p>\n

          20. Disclaimer<\/p>\n

          21. About DelveInsight<\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           DelveInsight Business Research LLP<\/a>
          Contact Person:<\/strong> Kritika Rehani
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 9193216187
          Address:<\/strong>304 S. Jones Blvd #2432
          City:<\/strong> Las Vegas
          State:<\/strong> Nevada
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.delveinsight.com\/<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          DelveInsight Business Research LLP DelveInsight\u2019s \u201cPrimary Sclerosing Cholangitis (PSC) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544610","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544610"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544610\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}